Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran

Journal of Nuclear Medicine

Volumn 41, Issue 7, 2000, Pages 1264-1270

  Line, Bruce R ^a   Weber, Peter B ^a   Lukasiewicz, Roberta ^a   Dansereau, Raymond N ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Antifibrin antibody; Dextran; Image background; Intravascular targeting; Radiopharmaceutical

Indexed keywords

DEXTRAN 70; DEXTRAN TC 99M; FIBRIN ANTIBODY; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOISOTOPE DISTRIBUTION; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; DEXTRANS; FIBRIN; IMMUNOGLOBULIN FAB FRAGMENTS; ORGANOTECHNETIUM COMPOUNDS; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS; TISSUE DISTRIBUTION;

EID: 0033912281     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sherwood RF, Baird JK, Atkinson T, Wiblin CN, Rutter DA, Ellwood DC. Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran. J Biochem. 1977;164:461-464.
2. Klotz U, Kroemer H. Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet. 1987;12:123-135.
3. Mehvar R, Robinson MA, Reynolds JM. Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J Pharm Sci. 1994;83:1495-1499.
4. Mishler JM. Synthetic plasma volume expanders: their pharmacology, safety and clinical efficacy. Clin Haematol. 1984;13:75-92.
5. Nishikawa M, Yamashita F, Takakura Y, Hashida M, Sezaki H. Demonstration of the receptor-mediated hepatic uptake of dextran in mice. J Pharm Pharmacol. 1992;44:396-401.
6. Yamaoka T, Kuroda M, Tabata Y, Ikada Y. Body distribution of dextran derivatives with electric charges after intravenous administration. Int J Pharm. 1995;113:149-157.
7. Bayley H, Standring DN, Knowles JR. Propane-1,3-dithiol: a selective reagent for the efficient reduction of alkyl and aryl azides to amines. Tetrahedron Lett. 1978;39:3633-3634.
8. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugar and related substances. Anal Chem. 1956;28:530-356.
9. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzene sulfonic acid. Anal Biochem. 1966;14:328-336.
10. Lei K, Rusckowski M, Chang F, Qu T, Mardirossian G, Hnatowich DJ. Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. Nucl Med Biol. 1996;23:917-922.
11. Rhodes BA, Zamora PO, Newell KD, Valdez EF. Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med. 1986;27:685-693.
12. Knight LC, Maurer AH, Ammar IA, Shealy DJ, Mattis JA. Evaluation of indium-111-labeled anti-fibrin antibody for imaging vascular thrombi. J Nucl Med. 1988;29:494-502.
13. Line BR, Herrmannsdoerfer AJ, Battles AH, Weber PB, Dansereau RN, Blumenstock FA. Premortem biodistribution of radioactivity in the rat: measurement of blood and tissue activity of tracers used in clinical imaging studies. Lab Anim Sci. 1994;44:495-502.
14. Moser KM. Venous thromboembolism. Am Rev Respir Dis. 1990;141:235-249.
15. Laroche Y, Demaeyer M, Stassen JM, et al. Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. J Biol Chem. 1991;266:16343-16349.
16. Holvoet P, Collen D. Immunoscintigraphy of thrombi [editorial] J Nucl Med. 1991;32:2321-2323.
17. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res. 1986;46:3969-3978.
18. Lister-James J, Vallabhajosula S, Moyer BR, et al. Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide. J Nucl Med. 1997;38:105-111.
19. Mehvar R, Shepard TL. Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats. J Pharm Sci. 1992;81:908-912.
20. Stock RJ, Cilento EV, McCuskey RS. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver. Hepatology. 1989;9:75-82.
21. Nishida K, Mihara K, Takino T, et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res. 1991;8:437-444.
22. Mehvar R, Reynolds JM. Pharmacokinetics of 70-kilodalton fluorescein-dextran in experimental diabetes mellitus. J Pharmacol Exp Ther. 1993;264:662-669.